Today: 7 February 2026
Subscribe
Browse Category

NASDAQ:ARTV News 17 October 2025 - 16 December 2025

Artiva Biotherapeutics (ARTV) Stock: Today’s News (Dec. 16, 2025), Why Shares Spiked, Analyst Forecasts, and What Investors Are Watching Next

Artiva Biotherapeutics (ARTV) Stock: Today’s News (Dec. 16, 2025), Why Shares Spiked, Analyst Forecasts, and What Investors Are Watching Next

Artiva Biotherapeutics, Inc. (NASDAQ: ARTV) is back on traders’ radars on December 16, 2025, after a sharp, high-volume move that has pushed the clinical-stage biotech into “crowded trade” territory—where catalysts, liquidity, and sentiment can matter as much as fundamentals. As of this morning, ARTV is trading around $6.30. That price level matters because it follows a session marked by unusually heavy volume and extreme intraday swings, and it arrives alongside fresh SEC disclosure of an insider transaction—two ingredients that often amplify attention in small- and mid-cap biotech. ARTV stock price today: the move that put Artiva back in the spotlight
16 December 2025
·····
Artiva Biotherapeutics (ARTV) Stock Skyrockets on FDA Fast Track News – What’s Next for Investors?

Artiva Biotherapeutics (ARTV) Stock Skyrockets on FDA Fast Track News – What’s Next for Investors?

In summary, Artiva Biotherapeutics stock has erupted in October 2025 on the back of a major FDA Fast Track win and renewed optimism around its NK-cell therapy for RA. The latest developments – from surging share price and volume to analyst projections of multi-fold upside – underscore the high stakes and high hopes riding on AlloNK’s success. For biotech investors and observers, ARTV will be a stock to watch closely in the coming months, as upcoming trial data and FDA feedback chart the next chapter for this promising yet still speculative biotech play. Latest Stock Price and Trend Analysis 247marketnews.com
17 October 2025
·····

Stock Market Today

Verizon stock price snaps 7-day run as consumer chief exit sharpens focus on turnaround

Verizon stock price snaps 7-day run as consumer chief exit sharpens focus on turnaround

7 February 2026
New York, February 6, 2026, 21:06 EST — Market closed. Verizon Communications Inc shares fell 1.7% on Friday to $46.31, snapping a seven-day streak of gains and pulling back from a one-year high set a day earlier. (MarketWatch) The dip followed a sharp late-January run-up that pushed the stock back into the mid-$40s. Verizon has climbed about 16% since its January 29 close of $39.81, leaving little room for stumbles as traders position for the week ahead. (Investing.com) The latest wrinkle is a leadership change at Verizon’s consumer business, the latest sign of an overhaul under CEO Dan Schulman. Consumer
Cisco stock jumps 3% near $85 as UBS sticks with Buy ahead of Feb. 11 earnings

Cisco stock jumps 3% near $85 as UBS sticks with Buy ahead of Feb. 11 earnings

7 February 2026
Cisco shares rose 3% to $84.82 Friday, nearing $85 ahead of fiscal Q2 results due Feb. 11. UBS maintained a Buy rating and $90 target, citing strong product order growth and data-center demand. Investors are watching AI-related spending and U.S. economic data that could affect rates. Peers Fortinet, CrowdStrike, and Palo Alto Networks also gained.
Coherent stock whiplash: COHR jumps after earnings drop — what to watch next week

Coherent stock whiplash: COHR jumps after earnings drop — what to watch next week

7 February 2026
Coherent Corp shares jumped 8.8% to $227.68 Friday, rebounding after a two-day slide following its quarterly results. The company reported December-quarter revenue of $1.69 billion and non-GAAP earnings of $1.29 a share, with datacenter and communications driving 72% of sales. Barclays, Stifel, and JPMorgan raised price targets to $235–$245. FMR LLC disclosed a 15% stake as of Dec. 31.
Go toTop